W. Bao

631 total citations
23 papers, 395 citations indexed

About

W. Bao is a scholar working on Hepatology, Epidemiology and Rheumatology. According to data from OpenAlex, W. Bao has authored 23 papers receiving a total of 395 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Hepatology, 9 papers in Epidemiology and 6 papers in Rheumatology. Recurrent topics in W. Bao's work include Hepatitis C virus research (11 papers), Hepatitis B Virus Studies (8 papers) and Liver Disease Diagnosis and Treatment (5 papers). W. Bao is often cited by papers focused on Hepatitis C virus research (11 papers), Hepatitis B Virus Studies (8 papers) and Liver Disease Diagnosis and Treatment (5 papers). W. Bao collaborates with scholars based in United States, Switzerland and Germany. W. Bao's co-authors include Gerald S. Berenson, Edward Gane, Henry Lik‐Yuen Chan, Aldo Trylesinski, S. R. Srinivasan, X. Jiang, Sukanya Srinivasan, Berenson Gs, C.E.M. Griffiths and Jinlin Hou and has published in prestigious journals such as American Journal of Epidemiology, European Heart Journal and Journal of Hepatology.

In The Last Decade

W. Bao

20 papers receiving 384 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
W. Bao United States	11	228	226	63	47	46	23	395
Elena Vezali Greece	10	217 1.0×	184 0.8×	13 0.2×	44 0.9×	11 0.2×	18	319
Elisa Bartolini Italy	13	294 1.3×	172 0.8×	17 0.3×	9 0.2×	47 1.0×	28	443
Amalia Levy Israel	7	100 0.4×	59 0.3×	22 0.3×	22 0.5×	95 2.1×	12	340
M.A.K. Rumi Bangladesh	8	139 0.6×	52 0.2×	15 0.2×	22 0.5×	49 1.1×	15	365
Mohammad Reza Ghadir Iran	12	174 0.8×	132 0.6×	17 0.3×	10 0.2×	21 0.5×	49	413
Elsemieke de Vries Netherlands	7	156 0.7×	179 0.8×	13 0.2×	10 0.2×	13 0.3×	9	342
Margarita Dehesa-Violante Mexico	11	175 0.8×	160 0.7×	20 0.3×	33 0.7×	6 0.1×	24	314
Anastasios Roussos Greece	10	94 0.4×	62 0.3×	118 1.9×	6 0.1×	32 0.7×	12	474
Eirini Kyrana United Kingdom	7	119 0.5×	90 0.4×	19 0.3×	19 0.4×	28 0.6×	24	243
Christine A. Morris United Kingdom	9	181 0.8×	234 1.0×	23 0.4×	29 0.6×	21 0.5×	16	411

Countries citing papers authored by W. Bao

Since Specialization

Citations

This map shows the geographic impact of W. Bao's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by W. Bao with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites W. Bao more than expected).

Fields of papers citing papers by W. Bao

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by W. Bao. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by W. Bao. The network helps show where W. Bao may publish in the future.

Co-authorship network of co-authors of W. Bao

This figure shows the co-authorship network connecting the top 25 collaborators of W. Bao. A scholar is included among the top collaborators of W. Bao based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with W. Bao. W. Bao is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Bao, W., Yoshimasa Ito, Kazuo Takahashi, et al.. (2025). Bisecting GlcNAc modification of angiotensin-related glycoproteins in mouse kidney. The Journal of Biochemistry. 178(3). 181–192.

Bao, W., Miyako Nakano, Masamichi Nagae, et al.. (2024). The K346T mutant of GnT-III bearing weak in vitro and potent intracellular activity. Biochimica et Biophysica Acta (BBA) - General Subjects. 1868(9). 130663–130663. 2 indexed citations

Goupille, P., Laura C. Coates, Jordi Gratacós, et al.. (2021). POS1044 EFFECT OF SECUKINUMAB VERSUS ADALIMUMAB ON ACR CORE COMPONENTS AND HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH PSORIATIC ARTHRITIS: RESULTS FROM THE EXCEED STUDY. Annals of the Rheumatic Diseases. 80. 797–798. 2 indexed citations

Gottlieb, Alice B., Joseph F. Merola, Kristian Reich, et al.. (2021). Efficacy of secukinumab and adalimumab in patients with psoriatic arthritis and concomitant moderate‐to‐severe plaque psoriasis: results from EXCEED, a randomized, double‐blind head‐to‐head monotherapy study. British Journal of Dermatology. 185(6). 1124–1134. 26 indexed citations

Deodhar, Atul, Iain B. McInnes, Xenofon Baraliakos, et al.. (2020). FRI0272 SECUKINUMAB DEMONSTRATES A CONSISTENT SAFETY PROFILE IN PATIENTS WITH PSORIASIS, PSORIATIC ARTHRITIS AND ANKYLOSING SPONDYLITIS OVER LONG TERM: UPDATED POOLED SAFETY ANALYSES. Annals of the Rheumatic Diseases. 79. 722–722. 4 indexed citations

Pascual‐Figal, Domingo A., W. Bao, Michele Senni, et al.. (2019). 1410Clinical predictors of NT-proBNP response to early initiation of sacubitril/valsartan after hospitalisation for decompensated heart failure: An analysis of the TRANSITION study. European Heart Journal. 40(Supplement_1). 1 indexed citations

Wachter, Rolf, Domingo A. Pascual‐Figal, Jan Bělohlávek, et al.. (2019). P773Initiation of sacubitril/valsartan and optimisation of evidence-based heart failure therapies after hospitalisation for acute decompensated heart failure: An analysis of the TRANSITION study. European Heart Journal. 40(Supplement_1). 1 indexed citations

Yu, Jian‐Wu, Micha Levi, Craig A. Hurwitz, et al.. (2013). 849 ALISPORIVIR INTERFERON-FREE TREATMENT ACHIEVED COMPARABLE EARLY HCV CLEARANCE RATES IN BOTH IL28CC AND IL28 CT/TT PATIENTS INFECTED WITH GENOTYPE 2/3 HCV. Journal of Hepatology. 58. S348–S348.

Gallay, Philippe, Michael Bobardt, Federico Bolognani, et al.. (2013). 833 DOWN-REGULATION OF INTERFERON-STIMULATED GENES AFTER ALISPORIVIR INTERFERON-FREE TREATMENT SUGGESTS A UNIQUE ANTIVIRAL MECHANISM OF ACTION FOR ALISPORIVIR, A CYCLOPHILIN INHIBITOR. Journal of Hepatology. 58. S342–S342. 1 indexed citations

10.

Griffel, Louis, W. Bao, R. Orsenigo, et al.. (2013). 821 INTERFERON (IFN)-FREE ALISPORIVIR (ALV) HAS A BETTER OVERALL SAFETY PROFILE COMPARED TO IFN-CONTAINING TREATMENT: A POOLED ANALYSIS OF THE ALV DEVELOPMENT PROGRAM. Journal of Hepatology. 58. S336–S337. 10 indexed citations

11.

Thongsawat, Satawat, Edward Gane, Yun‐Fan Liaw, et al.. (2012). Efficacy and safety of continuous 4‐year telbivudine treatment in patients with chronic hepatitis B. Journal of Viral Hepatitis. 20(4). e37–46. 63 indexed citations

12.

Chan, Henry Lik‐Yuen, Edward Gane, Shiv Kumar Sarin, et al.. (2012). Randomized clinical trial: efficacy and safety of telbivudine and lamivudine in treatment‐naïve patients with HBV‐related decompensated cirrhosis. Journal of Viral Hepatitis. 19(10). 732–743. 79 indexed citations

13.

Hou, Jiajie, Dong Xu, Zachary Goodman, et al.. (2011). 716 FIVE-YEAR TELBIVUDINE TREATMENT WITH EFFECTIVE VIRAL SUPPRESSION RESULTS IN RESOLUTION OF LIVER INFLAMMATION AND FIBROSIS REGRESSION IN PATIENTS WITH CHRONIC HEPATITIS B. Journal of Hepatology. 54. S287–S287. 5 indexed citations

14.

Flisiak, Robert, Jean–Michel Pawlotsky, R. Crabbé, et al.. (2011). 4 ONCE DAILY ALISPORIVIR (DEB025) PLUS PEGIFNALFA2A/RIBAVIRIN RESULTS IN SUPERIOR SUSTAINED VIROLOGIC RESPONSE (SVR24) IN CHRONIC HEPATITIS C GENOTYPE 1 TREATMENT NAIVE PATIENTS. Journal of Hepatology. 54. S2–S2. 46 indexed citations

15.

Gane, Edward, Henry Lik‐Yuen Chan, G Choudhuri, et al.. (2010). 7 TREATMENT OF DECOMPENSATED HBV-CIRRHOSIS: RESULTS FROM 2-YEARS RANDOMIZED TRIAL WITH TELBIVUDINE OR LAMIVUDINE. Journal of Hepatology. 52. S4–S4. 13 indexed citations

16.

Wursthorn, Karsten, et al.. (2010). 1033 QUANTITATIVE SERUM HBEAG MONITORING DURING TELBIVUDINE TREATMENT CORRELATES WITH VIROLOGICAL OUTCOMES. Journal of Hepatology. 52. S400–S400. 1 indexed citations

17.

Hsu, Chao‐Wei, Yun‐Fan Liaw, Edward Gane, et al.. (2009). 911 PROLONGED EFFICACY AND SAFETY OF 3 YEARS OF CONTINUOUS TELBIVUDINE TREATMENT IN POOLED DATA FROM GLOBE AND 015 STUDIES IN CHRONIC HEPATITIS B PATIENTS. Journal of Hepatology. 50. S331–S331. 16 indexed citations

18.

Hsu, Chao‐Wei, Yun‐Fan Liaw, Lai Wei, et al.. (2009). 906 EFFICACY OF 3 YEARS OF TELBIVUDINE TREATMENT FOR PATIENTS WITH GENOTYPE B/C CHRONIC HEPATITIS B (CHB). Journal of Hepatology. 50. S329–S329.

19.

Gs, Berenson, W. Bao, & Sukanya Srinivasan. (1996). Abnormal Characteristics in Young Offspring of Parents with Non-lnsulindependent Diabetes Mellitus: The Bogalusa Heart Study. American Journal of Epidemiology. 144(10). 962–967. 20 indexed citations

20.

Berenson, Gerald S., et al.. (1994). Epidemiology of early primary hypertension and implications for prevention: the Bogalusa Heart Study.. PubMed. 8(5). 303–11. 37 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact